title: Autologous serum eye drops for dry eye.
abstract: BACKGROUND
  =Theoretically, autologous serum eye drops (AS) have a potential advantage over traditional therapies based on the assumption that ASserve not only as a lacrimal substitute to provide lubrication, but also contain other biochemical components mimicking natural tears more closely. The application of AS in dry eye treatment has gained popularity as a second-line therapy in the treatment of dry eye.Published studies on the subject indicate that autologous serum could be an effective treatment for dry eye.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of AS compared to artificial tears for treating dry eye.
  
  
  METHODS
  We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 3),Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE,(January 1950 to April 2013), EMBASE (January 1980 to April 2013), Latin American and Caribbean Literature on Health Sciences(LILACS) (January 1982 to April 2013), themetaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov(www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We also searched the Science Citation Index Expanded database (September 2013) and reference lists of included studies. We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 15 April 2013.
  
  
  METHODS
  We included randomized controlled trials (RCTs) in which AS was compared to artificial tears in the treatment of dry eye in adults.
  
  
  METHODS
  Two review authors independently screened all titles and abstracts and assessed full-text articles of potentially eligible trials. Two review authors extracted data and assessed the methodological quality and characteristics of the included trials.We contacted investigators for missing data. For both primary and secondary outcomes, we reported mean differences with corresponding 95% confidence intervals(CIs) for continuous outcomes.
  
  
  RESULTS
  We identified four eligible RCTs in which AS was compared with artificial tear treatment or saline in individuals (n = 72 participants)with dry eye of various etiologies (Sjögren’s syndrome-related dry eye, non-Sjögren’s syndrome dry eye and postoperative dry eye induced by laser-assisted in situ keratomileusis (LASIK)). The quality of the evidence provided by these trials was variable. A majority of the risk of bias domains were judged to have an unclear risk of bias in two trials owing to insufficient reporting of trial characteristics.One trial was considered to have a low risk of bias for most domains while another was considered to have a high risk of bias for most domains. Incomplete outcome reporting and heterogeneity in the participant populations and follow-up periods prevented the inclusion of these trials in a summary meta-analysis. For the primary outcome, improvement in participant-reported symptoms at one month, one trial (12 participants) showed no difference in participant-reported symptoms between 20% AS and artificial tears. Based on the results of two trials in 32 participants, 20% AS may provide some improvement in participant-reported symptoms compared to traditional artificial tears after two weeks of treatment. One trial also showed positive results with a mean difference in tear breakup time (TBUT) of 2.00 seconds (95% CI 0.99 to 3.01 seconds) between 20% AS and artificial tears after two weeks, which were not similar to findings from the other trials. Based on all other objective clinical assessments included in this review, AS was not associated with improvements in aqueous tear production measured by Schirmer's test (two trials, 33 participants), ocular surface condition with fluorescein (four trials, 72 participants) or Rose Bengal staining (three trials, 60 participants), and epithelial metaplasia by impression cytology compared to artificial tears (one trial, 12 participants). Data on adverse effects were not reported by three of the included studies. In one study, there were no serious adverse events reported with the collection of and treatment with AS.
  
  
  CONCLUSIONS
  Overall there was inconsistency in the possible benefits of AS in improving participant-reported symptoms and TBUT and lack of effect based on other objective clinical measures. Well-planned, large, high-quality RCTs are warranted, in different severities of dry eye and using standardized questionnaires to measure participant-reported outcomes and objective clinical tests as well as objective biomarkers to assess the benefit of AS therapy for dry eye.
authors: Wilmer Eye Institute, Johns Hopkins University School of Medicine, 327 Maumenee Bldg, 600 N. Wolfe St., Baltimore, MD, USA, 21287-9238.
authors: Qing
authors: Q
authors: Pan
authors: Adla
authors: A
authors: Angelina
authors: Andrea
authors: A
authors: Zambrano
authors: Michael
authors: M
authors: Marrone
authors: Walter J
authors: WJ
authors: Stark
authors: Thomas
authors: T
authors: Heflin
authors: Li
authors: L
authors: Tang
authors: Esen K
authors: EK
authors: Akpek
mesh_terms: D000328:Adult; D015352:Dry Eye Syndromes / Q000628:therapy*; D006801:Humans; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D044967:Serum; D012965:Sodium Chloride / Q000627:therapeutic use
chemical_list: D009883:Ophthalmic Solutions; D012965:Sodium Chloride
references: Ophthalmic Plast Reconstr Surg. 2005 Jan;21(1):69-71
references: 15677957
references: Am Fam Physician. 2002 Sep 15;66(6):991-8
references: 12358224
references: Arch Ophthalmol. 1988 Oct;106(10):1423-5
references: 3052385
references: Z Laryngol Rhinol Otol. 1972 Jul;51(7):429-37
references: 5053112
references: Br J Ophthalmol. 1999 Apr;83(4):390-5
references: 10434857
references: Am J Ophthalmol. 1996 Jul;122(1):38-52
references: 8659597
references: Transfus Med. 2011 Aug;21(4):271-7
references: 21371142
references: Cornea. 2007 Aug;26(7):861-3
references: 17667623
references: Cochrane Database Syst Rev. 2010 Sep 08;(9):CD006775
references: 20824852
references: Arch Ophthalmol. 1988 Apr;106(4):484-7
references: 2451494
references: Clin Exp Ophthalmol. 2008 Nov;36(8):717-20
references: 19128374
references: Prog Retin Eye Res. 2000 Jan;19(1):113-29
references: 10614683
references: Am J Ophthalmol. 2003 Aug;136(2):318-26
references: 12888056
references: Ophthalmology. 1997 Sep;104(9):1395-401
references: 9307632
references: Ophthalmology. 2000 May;107(5):967-74
references: 10811092
references: Clin Exp Ophthalmol. 2008 Mar;36(2):119-22
references: 18352867
references: CLAO J. 1995 Oct;21(4):221-32
references: 8565190
references: J Cell Physiol. 1996 Oct;169(1):159-66
references: 8841432
references: Ocul Surf. 2006 Oct;4(4):188-95
references: 17146574
references: Ophthalmology. 2011 Jul;118(7):1242-52
references: 21459453
references: Graefes Arch Clin Exp Ophthalmol. 2005 Jul;243(7):706-14
references: 15756576
references: Am J Ophthalmol. 1992 Oct 15;114(4):441-7
references: 1415455
references: Int Ophthalmol Clin. 2000 Fall;40(4):113-22
references: 11064861
references: Aust N Z J Ophthalmol. 1987 Nov;15(4):257-62
references: 3435668
references: Optom Vis Sci. 1997 Aug;74(8):624-31
references: 9323733
references: Clin Dermatol. 2006 Sep-Oct;24(5):393-413
references: 16966020
references: J Refract Surg. 2006 Jan-Feb;22(1):61-6
references: 16447938
references: Acta Ophthalmol (Copenh). 1990 Feb;68(1):80-6
references: 2336939
references: Curr Opin Ophthalmol. 2004 Dec;15(6):503-7
references: 15523196
references: Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4753-61
references: 14578396
references: Arch Ophthalmol. 1983 Jul;101(7):1046-8
references: 6870626
references: Invest Ophthalmol Vis Sci. 2012 May 04;53(6):2601-6
references: 22427596
references: Am J Ophthalmol. 2007 Jul;144(1):86-92
references: 17493572
references: Cornea. 2008 Sep;27 Suppl 1:S25-30
references: 18813071
references: Graefes Arch Clin Exp Ophthalmol. 1998 Jan;236(1):1-8
references: 9457509
references: Br J Ophthalmol. 2004 Nov;88(11):1467-74
references: 15489495
references: Ophthalmologe. 2002 Dec;99(12):949-59
references: 12478384
references: Cornea. 2001 Nov;20(8):802-6
references: 11685055
references: FDA Consum. 2005 May-Jun;39(3):8-9
references: 16127813
references: Am J Ophthalmol. 1995 Mar;119(3):281-7
references: 7872387
references: Am J Ophthalmol. 2011 May;151(5):792-798.e1
references: 21310379
references: Ocul Surf. 2007 Apr;5(2):75-92
references: 17508116
references: Ophthalmologe. 2008 Jul;105(7):623-31
references: 18607606
references: Arch Soc Esp Oftalmol. 2011 Jan;86(1):3-7
references: 21414523
references: Cornea. 2013 Apr;32(4):412-8
references: 22955120
references: Br J Ophthalmol. 2001 Oct;85(10):1188-97
references: 11567963
references: Br J Ophthalmol. 1984 Sep;68(9):674-80
references: 6331845
references: Curr Eye Res. 2012 Aug;37(8):684-8
references: 22670856
references: Am J Med Sci. 2011 Jul;342(1):62-9
references: 21139494
references: Curr Opin Ophthalmol. 2004 Aug;15(4):299-304
references: 15232468
references: Am J Ophthalmol. 2005 Sep;140(3):565; author reply 565-6
references: 16139023
references: Ophthalmology. 2004 Jun;111(6):1115-20
references: 15177961
references: Am J Ophthalmol. 1987 Nov 15;104(5):494-501
references: 3674183
references: Ophthalmology. 2007 Jan;114(1):76-9
references: 17070588
references: Exp Eye Res. 2004 Mar;78(3):409-16
references: 15106920
references: Ophthalmology. 1999 Apr;106(4):803-10
references: 10201606
references: Br J Ophthalmol. 2004 May;88(5):647-52
references: 15090417
references: Bone Marrow Transplant. 2000 May;25(10):1101-3
references: 10828873
references: Clin Chim Acta. 1986 Jul 15;158(1):81-90
references: 3527488
references: Br J Ophthalmol. 2004 Apr;88(4):464-5
references: 15031155
references: Surv Ophthalmol. 2001 Mar;45 Suppl 2:S211-20
references: 11587145
references: Expert Opin Pharmacother. 2011 Feb;12(3):325-34
references: 21214414
references: Ocul Immunol Inflamm. 2007 Sep-Oct;15(5):389-93
references: 17972223
references: Cornea. 2010 Nov;29(11):1241-6
references: 20697273
references: Arch Ophthalmol. 1975 Oct;93(10):1039-43
references: 1180750
references: Cornea. 2004 Apr;23(3):272-85
references: 15084861
references: Klin Monbl Augenheilkd. 2005 Nov;222(11):901-4
references: 16308823
references: Arq Bras Oftalmol. 2008 Nov-Dec;71(6 Suppl):89-95
references: 19274418
references: Cornea. 2003 Oct;22(7):640-50
references: 14508260
references: Arch Ophthalmol. 2000 Dec;118(12):1632-8
references: 11115257
references: Cornea. 2007 Oct;26(9 Suppl 1):S13-5
references: 17881909
references: Bone Marrow Transplant. 2003 Apr;31(7):579-83
references: 12692625
references: Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4309-15
references: 17003420
references: Invest Ophthalmol Vis Sci. 1994 Mar;35(3):1046-58
references: 7510270
references: Am J Manag Care. 2008 Apr;14(3 Suppl):S88-101
references: 18452372
references: Pain. 1999 Oct;83(1):25-35
references: 10506669
references: Am J Ophthalmol. 2005 Feb;139(2):242-6
references: 15733983
references: Ophthalmology. 2003 Jun;110(6):1096-101
references: 12799232
references: Arch Soc Esp Oftalmol. 2004 Nov;79(11):537-42
references: 15578282
references: Am J Ophthalmol. 2004 Feb;137(2):337-42
references: 14962426
references: Cornea. 2006 Sep;25(8):900-7
references: 17102664
references: Cornea. 2010 Feb;29(2):133-40
references: 19966564
references: Prog Retin Eye Res. 2010 Jul;29(4):312-34
references: 20302969
references: Curr Eye Res. 2011 Sep;36(9):775-81
references: 21851164
references: Ophthalmology. 1998 Jun;105(6):1114-9
references: 9627665
references: J Med Libr Assoc. 2006 Apr;94(2):130-6
references: 16636704
references: Arq Bras Oftalmol. 2008 Nov-Dec;71(6 Suppl):47-54
references: 19274411
references: Arthritis Rheum. 1984 Apr;27(4):459-61
references: 6712760
references: J Refract Surg. 2004 May-Jun;20(3):270-5
references: 15188906
references: Clin Exp Ophthalmol. 2008 Mar;36(2):109-10
references: 18352864
references: Am J Ophthalmol. 1992 Jul 15;114(1):51-4
references: 1621785
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: Ophthalmol Clin North Am. 2003 Mar;16(1):29-35
references: 12683246
references: Ophthalmology. 2000 Apr;107(4):631-9
references: 10768324